MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12885-025-15193-7

Медицинская библиотека · BMC cancer · 2025

Androgenic effects of 11-oxyandrogens in castration-resistant prostate cancer.

Lapointe-Belleau Ariane, Rouleau Michèle, Villeneuve Lyne, Descarreaux Joseph, Caron Patrick, Beaudoin Caroline, Uchil Ashwini, Simonyan David, Dahmani Cylia, Joly-Beauparlant Charles, Gélinas Vincent, Droit Arnaud, Marcoux Nicolas, Castonguay Vincent, Lacombe Louis, Lévesque Éric, Guillemette Chantal

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Adrenal-derived 11-oxygenated androgens (11-oxyandrogens) emerged as potential key contributors to prostate cancer (PCa) progression by activating the androgen receptor (AR). This study investigates their clinical and mechanistic role in metastatic castration-resistant prostate cancer (mCRPC) patients initiating AR pathway inhibitors (ARPI).

METHODS

In a pilot study of 35 mCRPC patients initiating ARPI, serum steroids were quantified via mass spectrometry and correlated with survival. Functional assays assessed the proliferative effects of 11-oxyandrogens on CRPC cells and their inhibition by enzalutamide, supported by transcriptomic and proteomic profiling.

RESULTS

11-ketotestosterone (11KT) and its hydroxylated derivative, 11-hydroxytestosterone (11OHT) are the predominant potent androgens, accounting for 81% of circulating androgens. Higher baseline levels of 11KT, 11OHT, the abundant precursor 11β-hydroxyandrostenedione (11OHA4), and the downstream metabolite 11-hydroxyandrosterone (11OHAST) are linked to prolonged progression-free survival (PFS) (HR: 0.56–0.69; P < 0.05), suggesting an enhanced treatment response. 11KT and 11OHT promoted AR-driven proliferation of CRPC cells and gene expression, which was reversed by AR antagonism, suggesting they are primarily AR-mediated. Additionally, 11-oxyandrogens display distinct effects, including the activation of AR-independent pathways.

CONCLUSIONS

11-oxyandrogens are potent AR activators in mCRPC, with evidence suggesting they may exert distinct biological effects compared to canonical androgens. Their association with longer PFS and improved response to ARPI may reflect a more hormonally active tumor environment, potentially indicative of tumors with higher AR dependency and responsiveness to therapy. Their profiling may help predict ARPI response, warranting further investigation.

Для цитирования: Lapointe-Belleau Ariane, Rouleau Michèle, Villeneuve Lyne, Descarreaux Joseph, Caron Patrick, Beaudoin Caroline, Uchil Ashwini, Simonyan David, Dahmani Cylia, Joly-Beauparlant Charles, Gélinas Vincent, Droit Arnaud, Marcoux Nicolas, Castonguay Vincent, Lacombe Louis, Lévesque Éric, Guillemette Chantal. Androgenic effects of 11-oxyandrogens in castration-resistant prostate cancer.. BMC cancer. 2025. DOI: 10.1186/s12885-025-15193-7.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.